GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.

AP BIOSCIENCES INC. primarily focuses on the development of early-stage drug candidates through to preclinical trials, utilizing drug design and its two existing technology platforms to individually develop distinct monoclonal or bispecific antibody drugs tailored to promising targets, mechanisms of action, and disease characteristics.
AP BIOSCIENCES INC. possesses two technology platforms, both of which were independently developed by AP BIOSCIENCES INC. with full patent ownership:
1. OmniMab Library (Fully Human Antibody Library)
2. Target-Directed T-Cell Activation 3T Platform (T-cube Bispecific Antibody Platform)
New Drug R&D Products:
1. IBI302 (Anti-VEGF and Anti-Complement Bifunctional Recombinant Protein)
2. AP505/B1962 (PD-L1 x VEGF Bispecific Antibody)
3. AP203 (PD-L1 x CD137 Fully Human Bispecific Antibody)
4. AP402 (HER2v x CD137 Fully Human Bispecific Antibody)
5. AP601 (CD73 x CD137 Fully Human Bispecific Antibody)

HuniLife is committed to developing first-in-class therapeutics for unmet medical need, indicating the innovation-pursuing nature of HuniLife. The products in development at HuniLife are acquired from renowned research institutes or companies through lice

BIOGATE PRECISION MEDICINE CORP. has independently developed a specialized carrier protein that can effectively enhance the responsiveness of B cells to antigens (including autoantigens), thereby producing antibody drugs with high affinity and high specificity. The innovative design of this carrier protein successfully resolves the issue of low immunogenicity of autoantigens, significantly improving the efficiency and specificity of antibody production, while enhancing therapeutic efficacy and safety, to provide clinical applications with more precise and effective antibody drugs.